Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Posted: 9 January 2023 Immutep announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 protein, eftilagimod alpha (“efti”), in…
Cartherics to Present at Biotech Showcase 2023
Posted: 9 January 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners Cartherics, a biotechnology company developing immune cell therapies…
Ethics Approval received for Phase III Clinical Trial
Posted: 9 January 2023 Avecho Biotechnology Limited has announced that it has now received ethics approval for our Phase III clinical trial, testing oral CBD softgel capsule for insomnia. Avecho is on track to commence the largest randomised,…
Neuren IND submitted and first patients complete Phase 2 trials
Posted: 9 January 2023 Neuren Pharmaceuticals announced the submission of an Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome and provided an update on progress in its ongoing Phase 2 clinical trials for each of PhelanMcDermid,…
Collaboration with Leading Canadian Cancer Center Commences with Lecture from Supportive and Palliative Care Expert
Posted: 15 December Peter Mac continues to expand its global cancer network through a formal alliance partnership with one of the world’s leading cancer research centres, Toronto’s Princess Margaret Cancer Centre. Princess Margaret is the largest comprehensive cancer…
Campus Plus, Science and Technology Australia, and Cruxes Innovation to Deliver Industry PHD Program
Posted: 15 December Campus Plus, Science & Technology Australia, and Cruxes Innovation are delighted to have been chosen to deliver the new National Industry PhD program for the Department of Education. The National Industry PhD Program will powerfully…
Breaking ground: Moderna’s big build begins
Posted: 14 December In an important milestone for securing access to mRNA vaccines and enhancing medical research and development in Australia, global biotech Moderna has commenced construction of its new manufacturing facility at Monash University’s Clayton campus in…
CSL opens new Australian Plasma Fractionation Facility
Posted: 14 December CSL has today unveiled the future of plasma manufacturing in Australia with the opening of their $900 million Plasma Fractionation Facility in Victoria, the largest of its kind in the Southern Hemisphere. This is part…
Could insulin come in a pill? How a molecule that mimics insulin may advance diabetes research
Posted: 14 December WEHI researchers have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill. The…
Positive AZD0466 clinical data presented by AstraZeneca
Posted: 14 December Starpharma announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting. The…
Clarity 2.0 COVID-19 Study Outcome
Posted: 14 December Dimertix Limited a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, confirmed that the CLARITY 2.0 investigator-led study of DMX-200200 in COVID-19 patients has reported top line data. In total, 49 patients were recruited…
Positive Results Confirm EXO-NET Utility for EV-Based Ovarian Cancer Test Development
Posted: 14 December INOVIQ Limited is pleased to announce that the Ovarian Cancer 97 study (OC97) has been completed by the Centre for Clinical Research, The University of Queensland (UQ), confirming the utility of EXO-NET for EV biomarker…
